New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
05:38 EDTTGTXTG Therapeutics reports compelling clinical data from TG-1101 Phase 2 study
TG Therapeutics announced preliminary clinical results from its ongoing Phase 2 study of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib. The overall response rate, or ORR, at the first planned efficacy assessment for the 10 evaluable patients was 90%. Of the 28 patients enrolled on study to date, including patients with high risk CLL, no patients have progressed while on the combination, with patients on study now for upwards of 5 months. TG-1101 in combination with ibrutinib was well tolerated in the 28 patients evaluable for safety, with Day 1 infusion related reactions, or IRR, being the most frequently reported adverse event for TG-1101. Updated data presented at the EHA meeting demonstrates an 89% nodal response rate with 8/9 CLL patients now achieving a nodal or partial response on TGR-1202 monotherapy at doses greater than or equal to 800 mg.
News For TGTX From The Last 14 Days
Check below for free stories on TGTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
14:10 EDTTGTXTG Therapeutics SPA for CLL study earlier than expected, says Ladenburg
Ladenburg said TG Therapeutics reached an agreement with the FDA regarding a Special Protocol Assessment, or SPA, for a trial of its combo treatment for Chronic Lymphocytic Leukemia, or CLL, "quite ahead" of the firm's December expectation. The firm believes there is a relatively high probability for TG's combo to meet the specified primary endpoint and increased its price target on the stock to $22 from $18.
07:03 EDTTGTXTG Therapeutics announces SPA agreement with FDA for Phase 3 trial of TG-1101
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use